Research & Development
Immune System Diseases
CRISPR may enable rapid, sensitive test for COVID-19
The device has the potential for use as a diagnostic test at the point of care (POC), according to its developers.
September 26, 2022
N-antigen levels point to COVID severity in NIH study
The study by researchers at the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) was a cross-sectional follow-up analysis involving 2,540 participants who had been previously enrolled in the Therapeutics for Inpatients with COVID-19 (TICO) platform trial.
September 8, 2022
Lunaphore, Nucleai to provide AI-based spatial biology analysis
Combining Lunaphore's Comet hyperplex staining and imaging platform, a fully automated sequential immunofluorescence (seqIF) instrument, with Nucleai's Atom artificial-intelligence (AI) spatial biology platform will enable the companies to generate new insights from tissue biopsies and provide labs with an integrated end-to-end spatial biology workflow.
September 8, 2022
Week in Review: Room-temperature CRISPR, Roche T-cell test for COVID response, Qiagen monkeypox syndromic panel, and more
Dear LabPulse.com member,
August 17, 2022
Qiagen marks milestone for TB blood test
The fourth-generation QuantiFeronTB Gold Plus assay is being used to test patients in over 130 countries, the company said. It identifies interferon-gamma released by T cells after recognizing TB-specific antigens as a marker of TB infection.
March 23, 2022
'Rogue antibodies' hint at severe COVID risk
The goal of the study was to identify circulating factors, such as hormones and antibodies, in COVID-19 patients that contribute to the activation and dysfunction of endothelial cells, which are the main type of cell found in the inside lining of blood vessels, lymph vessels, and the heart.
February 16, 2022
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
AMP 2021 meeting puts spotlight back on cancer
Seminars at AMP 2021 focused on technologies and techniques to help detect and profile tumors, with special emphasis on hard-to-detect cancer cells that remain in patients after treatment.
November 22, 2021
Qiagen debuts solution for SARS-CoV-2 T-cell research
QuantiFeron SARS-CoV-2 ROU is a modular system based on the platform Qiagen developed for its QuantiFeron-TB Gold Plus test for latent tuberculosis.
December 6, 2020
Vaccines won't eliminate the need for COVID-19 testing
It may be natural to suspect that if a vaccine is available, there will be fewer cases thus less reason to test. But this isn't normally the interplay between vaccines and diseases.
November 23, 2020
Who should get the 1st COVID-19 vaccines?
Current strategic prioritization plans emphasize the importance of vaccinating healthcare workers, since doing so preserves the healthcare system itself. Another priority is to directly protect the elderly and people with comorbidities, who are at the highest risk of death or hospitalization from COVID-19.
October 25, 2020
Interleukin-6 testing grows rapidly, with limited evidence of utility
Cytokines are small proteins released by many different types of cells, including the white blood cells of the immune system. Cytokines help regulate the immune system's response to an infection and cause inflammation. The storm happens when the release of cytokines goes into an uncontrolled overdrive causing hyperinflammation which damages the body's organs. In the lungs, this inflammation causes fluid to accumulate in the airspaces which then leads to ARDS.
June 8, 2020
Sequencing seeks to stay ahead of new COVID-19 surges
Sequencing has been an essential tool for the development of strategies and therapeutics in the fight against COVID-19, and sequencing-based rapid and high-throughput diagnostics for COVID-19 are in development. Sequencing technology suppliers are collaborating with researchers to develop sequencing-based diagnostic tools. For example, several groups are using Illumina's next-generation sequencing (NGS) technology to develop ultrahigh-throughput COVID-19 diagnostic testing.
June 7, 2020
Page 1 of 3